Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
Authors:
- Davide SaronniDSDavide Saronni
- Germano GaudenziGGGermano Gaudenzi
- Alessandra DicitoreADAlessandra Dicitore
- Silvia CarraSCSilvia Carra
- Maria Celeste CantoneMCMaria Celeste Cantone
- Maria Orietta BorghiMBMaria Orietta Borghi
- Andrea BarbieriABAndrea Barbieri
- Luca MignaniLMLuca Mignani
- Leo J. HoflandLHLeo J. Hofland
- Luca PersaniLPLuca Persani
- Giovanni VitaleGiovanni Vitale
Open Access
Abstract
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from parafollicular C cells of the thyroid gland. In this preclinical study, we tested three tyrosine-kinase inhibitors (TKIs): SU5402, a selective inhibitor of fibroblast growth factor receptor (FGFR)-1 and vascular endothelial growth factor receptor (VEGFR)-2; sulfatinib, an inhibitor of FGFR-1 and VEGFR-1, -2, -3; and SPP86, a RET-specific inhibitor. The effects of these compounds were evaluated in vitro in two human MTC cell lines (TT and MZ-CRC-1), and in vivo using xenografts of MTC cells in zebrafish embryos. SU5402, sulfatinib and SPP86 decreased cell viability. Sulfatinib and SPP86 significantly induced apoptosis in both cell lines. Sulfatinib and SPP86 inhibited the migration of TT and MZCRC-1 cells, while SU5402 was able to inhibit migration only in TT cells. In vivo we observed a significant reduction in TT cell-induced angiogenesis in zebrafish embryos after incubation with sulfatinib and SPP86. In conclusion, sulfatinib and SPP86 displayed a relevant antitumor activity both in vitro and in vivo. Moreover, this work suggests the potential utility of targeting FGFR and VEGFR signaling pathways as an alternative therapy for MTC.Keywords
Funding Information
- Italian Ministry of Health (IRCCS funding Ricerca Corrente, ZEBRANET)
- Italian Ministry of Education, University and Research (PRIN 2017Z3N3YC)
This publication has 69 references indexed in Scilit:
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid CarcinomaThyroid®, 2010
- Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasisEndocrine-Related Cancer, 2010
- The role of the VEGF-C/VEGFR-3 axis in cancer progressionBritish Journal of Cancer, 2006
- Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumorsAnnals of Oncology, 2005
- VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanismsLaboratory Investigation, 2005
- Matrix Metalloproteinases, Tissue Inhibitors of Matrix Metalloproteinases and Angiogenic Cytokines in Peripheral Blood of Patients with Thyroid CancerThyroid®, 2002
- Slow Release Lanreotide in Combination with Interferon- 2b in the Treatment of Symptomatic Advanced Medullary Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2000
- Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell linesCancer Genetics and Cytogenetics, 1995